These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 4600292)

  • 1. Short-term effects of 1,25-dihydroxycholecalciferol on disordered calcium metabolism of renal failure.
    Brickman AS; Coburn JW; Norman AW; Massry SG
    Am J Med; 1974 Jul; 57(1):28-33. PubMed ID: 4600292
    [No Abstract]   [Full Text] [Related]  

  • 2. Action of 1,25-dihydroxycholecalciferol in normal and uraemic man.
    Coburn JW; Brickman AS; Massry SG; Singer FR; Norman AW
    Proc Eur Dial Transplant Assoc; 1973; 10(0):210-6. PubMed ID: 4802387
    [No Abstract]   [Full Text] [Related]  

  • 3. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D3, in uremic man.
    Brickman AS; Coburn JW; Norman AW
    N Engl J Med; 1972 Nov; 287(18):891-5. PubMed ID: 4342432
    [No Abstract]   [Full Text] [Related]  

  • 4. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
    Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
    Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
    [No Abstract]   [Full Text] [Related]  

  • 5. Calcitriol in disorders of bone and calcium metabolism.
    Riggs BL
    Clin Ther; 1980; 3(1):33-9. PubMed ID: 6893296
    [No Abstract]   [Full Text] [Related]  

  • 6. The clinical use of synthetic 1,25-dihydroxycholecalciferol.
    Evans IM; Boulton-Jones M; Doyle FH; Joplin GF; Lockwood M; Matthews EW; MacIntyre I
    Calcif Tissue Res; 1976 Aug; 21 Suppl():236-41. PubMed ID: 782663
    [No Abstract]   [Full Text] [Related]  

  • 7. Calcifediol (25-hydroxyvitamin D3) in the treatment of uremic bone disease.
    Teitelbaum SL
    Ann Intern Med; 1981 Mar; 94(3):404-5. PubMed ID: 6894359
    [No Abstract]   [Full Text] [Related]  

  • 8. Requirements of vitamin D metabolites in patients with renal disease.
    Massry SG
    Am J Clin Nutr; 1980 Jul; 33(7):1530-5. PubMed ID: 6893103
    [No Abstract]   [Full Text] [Related]  

  • 9. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical and histological effects of 1,25 dihydroxycholecalciferol (1,25-DHCC) in the osteomalacia of chronic and failure.
    Eastwood JB; Phillips ME; de Wardener HE; Bordier J; Marie P; Arnaud CD; Norman AW
    J Urol Nephrol (Paris); 1974 Dec; 80(12):984-5. PubMed ID: 4617780
    [No Abstract]   [Full Text] [Related]  

  • 11. The kidney as an endocrine organ for the production of 1,25-dihydroxyvitamin D 3 , a calcium-mobilizing hormone.
    DeLuca HF
    N Engl J Med; 1973 Aug; 289(7):359-65. PubMed ID: 4578017
    [No Abstract]   [Full Text] [Related]  

  • 12. The biological activity and metabolism of 24,25-dihydroxyvitamin D 3 .
    Boyle IT; Omdahl JL; Gray RW; DeLuca HF
    J Biol Chem; 1973 Jun; 248(12):4174-80. PubMed ID: 4711602
    [No Abstract]   [Full Text] [Related]  

  • 13. [Intestinal absorption of Ca47 in chronic renal insufficiency before and after treatment with 1,25 dihydroxycholecalciferol].
    Vattimo A
    Minerva Med; 1979 Dec; 70(54):3705-7. PubMed ID: 523001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
    Malluche HH; Goldstein DA; Massry SG
    Contrib Nephrol; 1980; 18():98-104. PubMed ID: 7353383
    [No Abstract]   [Full Text] [Related]  

  • 15. Action of 1,25-dihydroxycholecalciferol in uraemia.
    Lancet; 1972 Dec; 2(7788):1185-6. PubMed ID: 4117601
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of vitamin D in idiopathic hypercalciuria.
    Maggio AJ; Coburn JW; Brosman SA; Das S
    J Urol; 1979 Aug; 122(2):147-51. PubMed ID: 222916
    [No Abstract]   [Full Text] [Related]  

  • 17. Interrelationships between the key elements of the vitamin D endocrine system: 25-OH-D3-1-hydroxylase, serum calcium and phosphorus levels, intestinal 1,25(OH)2D3, and intestinal calcium binding protein.
    Norman AW; Friedlander EJ; Henry H
    Adv Exp Med Biol; 1977; 81():211-31. PubMed ID: 331899
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance to parathyroid hormone in renal failure: role of vitamin D metabolites.
    Somerville PJ; Kaye M
    Kidney Int; 1978 Sep; 14(3):245-54. PubMed ID: 723151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Actions of 1,25-dihydroxycholecalciferol in patients with hypophosphatemic, vitamin-D-resistant rickets.
    Brickman AS; Coburn JW; Kurokawa K; Bethune JE; Harrison HE; Norman AW
    N Engl J Med; 1973 Sep; 289(10):495-8. PubMed ID: 4353218
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of 1,25-dihydroxycholecalciferol in renal osteopathy].
    Reutter FW; Sieber R; Olah AJ; Dambacher MA
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1880-3. PubMed ID: 531567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.